Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,935 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.
Sasaki N, Kuroda J, Nagoshi H, Yamamoto M, Kobayashi S, Tsutsumi Y, Kobayashi T, Shimura Y, Matsumoto Y, Taki T, Nishida K, Horiike S, Akao Y, Taniwaki M. Sasaki N, et al. Among authors: kobayashi s, kobayashi t. Exp Hematol. 2011 Aug;39(8):817-28.e1. doi: 10.1016/j.exphem.2011.05.002. Epub 2011 May 11. Exp Hematol. 2011. PMID: 21640157 Free article.
The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
Kobayashi T, Kuroda J, Fuchida S, Murakami S, Hatsuse M, Okano A, Iwai T, Tsutsumi Y, Kamitsuji Y, Akaogi T, Kawata-Iida E, Shimizu D, Uchiyama H, Matsumoto Y, Horiike S, Nakao M, Takahashi R, Kaneko H, Uoshima N, Kobayashi Y, Shimazaki C, Taniwaki M. Kobayashi T, et al. Among authors: kobayashi y. Intern Med. 2013;52(9):961-8. doi: 10.2169/internalmedicine.52.9385. Epub 2012 Mar 1. Intern Med. 2013. PMID: 23648714 Free article.
Rheumatoid arthritis/methotrexate-associated primary cutaneous diffuse large B-cell lymphoma, leg type.
Matsumoto Y, Horiike S, Maekawa S, Isohisa T, Sakamoto N, Chinen Y, Nakayama R, Kiyota M, Nagoshi H, Mizutani S, Shimura Y, Sugitani M, Kobayashi T, Nakai N, Kuroda J, Taniwaki M. Matsumoto Y, et al. Among authors: kobayashi t. Intern Med. 2014;53(11):1177-81. doi: 10.2169/internalmedicine.53.1735. Epub 2014 Jun 1. Intern Med. 2014. PMID: 24881744 Free article.
Clinical manifestation and prognostic factors of 32 Japanese patients with autoimmune disease-associated diffuse large B-cell lymphoma.
Maegawa S, Kuroda J, Kobayashi T, Fuchida S, Kawata E, Kamitsuji Y, Tsutsumi Y, Iwai T, Nakao M, Kaneko H, Uoshima N, Shimazaki C, Kobayashi Y, Horiike S, Yamamoto A, Kawahito Y, Taniwaki M. Maegawa S, et al. Among authors: kobayashi y, kobayashi t. Leuk Lymphoma. 2015 Mar;56(3):785-8. doi: 10.3109/10428194.2014.928936. Epub 2014 Jun 25. Leuk Lymphoma. 2015. PMID: 24884317 No abstract available.
Prognostic impact of a past or synchronous second cancer in diffuse large B cell lymphoma.
Tanba K, Chinen Y, Uchiyama H, Uoshima N, Shimura K, Fuchida S, Kiyota M, Nakao M, Shimura Y, Kobayashi T, Horiike S, Wada K, Shimazaki C, Kaneko H, Kobayashi Y, Taniwaki M, Kuroda J. Tanba K, et al. Among authors: kobayashi y, kobayashi t. Blood Cancer J. 2018 Jan 25;8(1):1. doi: 10.1038/s41408-017-0043-6. Blood Cancer J. 2018. PMID: 29367648 Free PMC article. Clinical Trial. No abstract available.
Chromosomal abnormality variation detected by G-banding is associated with prognosis of diffuse large B-cell lymphoma treated by R-CHOP-based therapy.
Mizuno Y, Tsukamoto T, Kawata E, Uoshima N, Uchiyama H, Yokota I, Maegawa S, Takimoto T, Tanba K, Matsumura-Kimoto Y, Kuwahara-Ota S, Fujibayashi Y, Yamamoto-Sugitani M, Chinen Y, Shimura Y, Horiike S, Taniwaki M, Kobayashi T, Kuroda J. Mizuno Y, et al. Among authors: kobayashi t. Cancer Med. 2018 Mar;7(3):655-664. doi: 10.1002/cam4.1342. Epub 2018 Feb 23. Cancer Med. 2018. PMID: 29473332 Free PMC article.
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators. Morschhauser F, et al. N Engl J Med. 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104. N Engl J Med. 2018. PMID: 30184451 Free PMC article. Clinical Trial.
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
Trotman J, Barrington SF, Belada D, Meignan M, MacEwan R, Owen C, Ptáčník V, Rosta A, Fingerle-Rowson GR, Zhu J, Nielsen T, Sahin D, Hiddemann W, Marcus RE, Davies A; PET investigators from the GALLIUM study. Trotman J, et al. Lancet Oncol. 2018 Nov;19(11):1530-1542. doi: 10.1016/S1470-2045(18)30618-1. Epub 2018 Oct 8. Lancet Oncol. 2018. PMID: 30309758
14,935 results
You have reached the last available page of results. Please see the User Guide for more information.